Saxenda, New Obesity Drug, Goes On Sale

4/22/2015 — Novo Nordisk A/S  launched its obesity drug Saxenda in the U.S., at a substantial price tag of $1,068 per month, according to a report by Reuters. The drug will enter an already crowded weight loss market, face physicians as well as patients who don’t really see obesity as a disease, at a premium price. Saxenda, a once-daily intravenous obesity treatment, was approved by the FDA in December last year.